Form 4 for NVCR NovoCure Ltd
Accepted 2025-01-03 00:00:00 ET · period of report 2025-01-01 · accession 0001562180-25-000065 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-01-03 | 2024-12-31+ | NVCR | Danziger Asaf | Dir | A - Grant | $0.0152 | +400.4K | 15.6K | New | +$6,077 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-01-01 | A | A | 400,000 | $0.00 | 415,640 | D | — | — | (F3) Represents restricted share units that are scheduled to vest in equal installments on December 31, 2025 and December 31, 2026, subject to the reporting person's continued employment through such dates. |
| 2 | Common | Ordinary Shares | 2024-12-31 | A | A | 412 | $14.75 | 15,640 | D | — | — | (F1) The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c). (F2) In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024. |